ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 694

Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE

George Stojan1, Jessica Li 2 and Michelle Petri 2, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Lupus, obesity and Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Obesity is more common in patients with SLE compared to the general population. The prevalence of obesity among SLE patients is between 28 and 50 percent. We previously demonstrated an inverse correlation between body mass index and disease activity in systemic lupus, even after adjusting for prednisone dose.  The question of whether these findings were epiphenomena related to disease activity itself remained unanswered. We thus hypothesized that the BMI at cohort entry was predictive of future disease activity.

Methods: 2406 patients in a prospective SLE cohort had their weight assessed at each visit. Patients were categorized into five predetermined groups based on weight: low (BMI< 20 kg/m2), normal weight (reference, BMI 20-24.9 kg/m2), overweight (25-29.9 kg/m2), obese (BMI 30-34.9 kg/m2), and severely obese (BMI >35 kg/m2). Disease activity was characterized on the basis of SLE Disease Activity Index (SLEDAI) scores; for each BMI category we created an Adjusted Mean SLEDAI score. This involved calculating the area under the curve of SLEDAI scores over time. The area under the curve between each two visits was the average of the SLEDAI values at those two visits multiplied by the length of time between the two visits. All the calculated areas were then summed and divided by the total length of the time period. The adjusted mean SLEDAI had the same units as SLEDAI. The adjusted mean SLEDAI has been shown to be a valid measure of SLE activity. To calculate adjusted mean of SLEDAI over time, we only included patients attending the clinic at 3 month intervals for a minimum of 3 visits. 1896 patients were included in the analysis. 1763 (93.0%) were females. Majority (53.0%) were Caucasians, 39.0% African American.  To determine whether BMI at cohort entry was predictive of future disease activity, we compared the categorized BMI at cohort entry with the adjusted mean SLEDAI by pairwise t test and ANOVA test. Data were adjusted for prednisone use at cohort entry.

Results: SLEDAI (adjusted mean) by Body Mass Index at baseline visit

BMI

N (%)

SLEDAI Mean (SD)

P value*

Low (Reference)

183(9.7)

2.9(2.2)

REF

Normal

655(34.5)

2.7(2.4)

0.1912

Overweight

531(28)

2.5(2.1)

0.0328

Obese

290(15.3)

2.6(2.1)

0.0464

Severely Obese

237(12.5)

2.5(2.1)

0.0755

*p-values adjusted for prednisone dose (as a continuous variable) at cohort entry

Conclusion: Body weight at cohort entry was predictive of future disease activity. Overweight and obese patients had a significantly lower adjusted mean SLEDAI over time (P< 0.05). This analysis adds further support to the existence of an obesity paradox in SLE.


Disclosure: G. Stojan, None; J. Li, None; M. Petri, Eli Lilly and Company, 5, Exagen, 2, 5.

To cite this abstract in AMA style:

Stojan G, Li J, Petri M. Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/body-mass-index-at-time-of-diagnosis-is-predictive-of-future-disease-activity-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/body-mass-index-at-time-of-diagnosis-is-predictive-of-future-disease-activity-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology